Startseite A novel frameshift mutation of the lecithin:cholesterol acyltransferase (LCAT) gene associated with renal failure in familial LCAT deficiency
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

A novel frameshift mutation of the lecithin:cholesterol acyltransferase (LCAT) gene associated with renal failure in familial LCAT deficiency

  • Bernhard U. Bender , Thomas Quaschning , Hartmut P.H. Neumann , Dieter Schmidt und Annette Kraemer-Guth
Veröffentlicht/Copyright: 17. April 2007
Veröffentlichen auch Sie bei De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Band 45 Heft 4

Abstract

Background: The lecithin:cholesterol acyltransferase (LCAT) gene is located on the long arm of chromosome 16 and encodes a highly conserved enzyme that catalyzes the formation of most plasma lipoprotein cholesteryl esters. Two autosomal recessive disorders, familial LCAT deficiency (FLD) and fish eye disease, are associated with germline LCAT mutations. Patients with FLD and fish-eye disease frequently present with corneal opacity, anemia and renal failure with proteinuria.

Methods: We clinically and biochemically characterized a German patient with classical FLD and used molecular genetic analysis to identify a novel homozygous LCAT mutation within codon 178.

Results: The insertion of adenine identified is located in one of the two motifs that resemble sequences found in several lipases, and results in a frameshift with a stop codon at residue 214. Therefore, the mutation alters a large portion of the LCAT enzyme, including both protein regions with putative lipase activity. Clinically, the female patient presented with corneal opacity, mild anemia and a slow deterioration in kidney function that led to a requirement for hemodialysis until she received a renal transplant.

Conclusions: The present data provide additional insights into the genotype/phenotype correlations of FLD and thus may improve the genetic diagnosis of this interesting inborn error of metabolism.

Clin Chem Lab Med 2007;45:483–6.


Corresponding author: PD Dr. Annette Kraemer-Guth, Medizinische Universitätsklinik, Hugstetterstr. 55, 79106 Freiburg, Germany Phone: +49-761-1303244, Fax: +49-761-131384,

Received: 2006-11-12
Accepted: 2007-1-16
Published Online: 2007-04-17
Published in Print: 2007-04-01

©2007 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Electrophoretic separations of cerebrospinal fluid proteins in clinical investigations
  2. Haemophilia A: molecular insights
  3. Quality specifications: self pleasure for clinical laboratories or added value for patient management?
  4. A724A polymorphism of sarco(endo)plasmic reticulum Ca2+-ATPase 2 (SERCA2) in hypertensive patients
  5. Associations of common polymorphisms in the thymidylate synthase, reduced folate carrier and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase genes with folate and homocysteine levels and venous thrombosis risk
  6. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPARγ-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population
  7. A novel frameshift mutation of the lecithin:cholesterol acyltransferase (LCAT) gene associated with renal failure in familial LCAT deficiency
  8. The c.–292C>T promoter polymorphism increases reticulocyte-type 15-lipoxygenase-1 activity and could be atheroprotective
  9. The genetic polymorphisms of β3-adrenergic receptor (AR) Trp64Arg and β2-AR Gln27Glu are associated with obesity in Chinese male hypertensive patients
  10. Diagnostic performance of combined specific urinary proteins and urinary flow cytometry in urinary tract pathology
  11. Diagnostic accuracy of the FIDIS multiplex fluorescent microsphere immunodetection system for anti-extractable nuclear antigen (ENA) antibodies in connective tissue diseases
  12. Fluorimetric quantitation of citalopram and escitalopram in plasma: developing an express method to monitor compliance in clinical trials
  13. Free serum cortisol: quantification applying equilibrium dialysis or ultrafiltration and an automated immunoassay system
  14. Percutaneous coronary intervention-induced variations in systemic parameters of inflammation: relationship with the mode of stenting
  15. Multicentre physiological reference values for the concentration of creatininium in plasma and diagnostic specificity of glomerular filtration rate estimated with the MDRD equation
  16. Serum levels of ischemia-modified albumin in healthy volunteers after exercise-induced calf-muscle ischemia
  17. Reference intervals for follicle-stimulating hormone, luteinizing hormone and prolactin in children and young adults on the bioMérieux Mini-Vidas system
  18. Limits of usual biochemical alcohol markers in cord blood at term: a fetal/maternal population-based study
  19. Implementing the Stockholm Conference hierarchy of objective quality criteria in a routine laboratory
  20. The diffusion of innovations theory could help laboratorians in research translation
  21. Detection of CYP2D6 polymorphisms *9, *10, and *41 using ARMS-PCR and their allelic frequencies in 400 psychiatric patients
  22. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method
  23. Measurement of free thyroxine in laboratory medicine – proposal of measurand definition
Heruntergeladen am 19.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.102/html?lang=de
Button zum nach oben scrollen